<DOC>
	<DOCNO>NCT02409524</DOCNO>
	<brief_summary>This open-label , single site , Phase II clinical trial investigate safety efficacy individualized anti-cancer vaccine ( CRCL-AlloVax ) advance HCC patient minimum 90 day sorafenib .</brief_summary>
	<brief_title>An Individualized Anti-Cancer Vaccine Advanced Hepatocellular Carcinoma Subjects</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) primary liver cancer third lead cause cancer death worldwide . It account 90 % liver cancer . More 80 % patient present advance unresectable disease . For patient vascular invasion and/or metastasis , approve therapy offer survival advantage Sorafenib ( Nexavar® ) . While palliative systemic chemotherapy Sorafenib sometimes offer HCC , evidence chemotherapy meaningful therapeutic benefit , especially overall survival . Subjects current study complete least 90 day sorafenib treatment . Subjects continue sorafenib tolerate receive experimental therapy . The experimental dosing schedule four segment : ( 1 ) priming , consist intradermal AlloStim alone ; ( 2 ) vaccination , consist intradermal dose AlloStim+CRCL ; ( 3 ) activation , consist intravenous infusion AlloStim ; ( 4 ) booster , consist monthly intradermal injection CRCL alone</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : 1 . Males female least 18 year age time enrollment 2 . Histologically confirm hepatocellular carcinoma without positive HBV and/or HCV 3 . Minimum 90 day sorafenib treatment unresectable 4 . ChildPugh Stage AB ( score ≥ 5 ≤ 9 ) 5 . Performance status : ECOG &lt; 2 deterioration previous 2 week 6 . Measurable disease ( RECIST ) 7 . Lesion amenable percutaneous tumor harvest follow biopsy 8 . Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; 10.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 75,000/μl ALT AST &lt; 2.5 x ULN Alkaline phosphatase &lt; 4 x ULN Serum creatinine &lt; 1.5 9 . Women childbearing potential : negative pregnancy test 10 . Patients child produce potential : usage contraception avoidance pregnancy measure enrol study receive experimental product 11 . Ability understand study , inherent risk , side effect potential benefit ability give write informed consent participate Exclusion criterion : 1 . Severe ascites , massive uncontrolled ( +3 ChildPugh calculator ) 2 . Severe encephalopathy , uncontrolled ( +3 ChildPugh calculator ) 3 . INR &gt; 1.5 4 . Participation another clinical trial evaluate experimental treatment procedure receive medication/treatment HCC sorafenib 5 . Any autoimmune disorder 6 . Any clinical condition require systemic steroid current immunosuppressive therapy , include : cyclosporine , antithymocyte globulin , tacrolimus within 1 month study entry 7 . HIV positive syphilis 8 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker Digoxin permit ) uncontrolled hypertension 9 . Active clinically serious infection ( &gt; grade 2 NCICTCAE version 4.0 ) 10 . History organ tissue allograft 11 . Advanced liver cirrhosis 12 . Interferon thalidomide within 1 month prior sign inform consent 13 . Uncontrolled concurrent serious medical psychiatric illness 14 . Clinically apparent central nervous system metastases carcinomatous meningitis 15 . History blood transfusion reaction 16 . Known allergy murine monoclonal antibody bovine product cow milk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>